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DThe type of MVoperation was reflective of surgeons’ pref-
erence and not standardized. A strength of this heterogene-
ity in approach, however, is that we were able to evaluate
approaches concurrently. We tried to compensate for bias
in patient selection by propensity matching patients with
similar comorbidities and similar extent of MV disease.
Long-term follow-up is needed to fully evaluate compara-
tive effectiveness of robotic MV repair.
CONCLUSIONS
Robotically assisted MV repair represents the least inva-
sive form ofMV surgery without a compromise in quality of
valve repair or patient safety, and should therefore be con-
sidered for all patients with severemyxomatousMV disease
and posterior leaflet prolapse. Ongoing refinements of ro-
botic instrumentation and development of ancillary technol-
ogies will facilitate wider adoption of this technique in
contemporary surgical practice.
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Dr Vivek Rao (Toronto, Ontario, Canada). The authors are to
be congratulated. There is clearly a patient- and provider-driven
desire to move toward minimally invasive surgery. Many studies,
including several from the Cleveland Clinic, have shown that
this can be done. I am pleased that the authors have now focused
their attention on whether or not this should be done.
I want to point out a few caveats. This is a study performed by
a large-volume center by several experienced valve surgeons. Their
outstanding clinical results include zero mortalities in 750 mitral
repairs and only 1 failure to repair a valve. Before we start taking
this procedure home to our own institutions, we have to keep that
in mind that in these excellent hands their results are spectacular.
Despite those spectacular clinical outcomes, there were certain
drawbacks to MV surgery done with robotic assistance. Clearly,
as you have shown, operative times are longer, cardiopulmonary
bypass times are longer, and ischemic times are longer, and this
in a cohort of patients who had relatively easy MVs to repair, iso-
lated posterior leaflet prolapse. Are these differences magnified
when we start to challenge the more complex MV?
Third, you indicated there was no significant difference in
bleeding or transfusion requirements among the groups; however,
it was interesting to note that massive transfusion requirements,
defined as more than 3 units of packed red blood cells, was actually
higher in the robotic group. Does that mean that when things go
bad with robotic surgery, things go really bad?
I also point out that the length of stay reductions that we ob-
served were less than overwhelming, an average of 1 median
day less, and what you did not present but was present in your ar-
ticle was that there was actually no difference in pain scores be-
tween robotic surgery and even complete sternotomy, and that
was somewhat surprising to me.ry c January 2011
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DThat leads me to question a few things about your study from
a philosophical nature. What is the real goal of robotic minimally
invasive surgery? Is it to improve the quality and the physiologic
recovery of patients or is it for cosmesis? If the former, a simple
walk through our exhibit hall will show many companies that
show sternal fixation devices that allow patients to go home 2 to
3 days after surgery, which would be a dramatic improvement
compared with even the excellent results that you show here.
Last, I caution people in compromising the integrity of their
overall medical management simply to achieve minimally invasive
surgery. If we can achieve similar results with good physiologic re-
covery with a full sternotomy and perform all the technical proce-
dures that are needed to be done on a patient, I think that should be
paramount. There is a tendency in the real world to compromise
our patients by doing, for example, a percutaneous stent to the
left anterior descending artery to facilitate port-access MV surgery
and perhaps not do what is in the best interest of our patients.
Once again, these are philosophical questions at most, and I
thank the Association for the privilege of discussing this article.
Dr Mihaljevic. Your first question is whether this is a cosmesis
versus quality. Our entire study was designed to show that there
was no compromise in quality. We report essentially 100% mitral
valve repair rate with zero mortality. It is difficult to argue that
there is a compromise in quality with such results.
It is also difficult to show, as you said, a spectacular reduction in
hospital length of stay for operations that normally do not require
a long hospital stay anyhow. So it is not to be expected that a patient
after general anesthetic and cardiopulmonary bypass is going to
leave the hospital on postoperative day 2 no matter what we do,
and you are right about that. I think one of the real advantages
of this approach, which is not analyzed in this study, is the fact
that these patients do return to their regular activities of daily
life substantially faster than those who have a complete sternot-
omy, and that has been our experience.
Now, as I said, when it comes to the bleeding, yes, we have had,
obviously, conversions. You have to understand that these are the
patients whom we analyzed with an intent to treat, so we have
not tried to hide the complications that occur with occasional con-
versions, but those were rare and they have not compromised the
overall outcome of our patients in this study, as I hope that this
is well documented with our results and analysis.
DrHarold Roberts (Lauderdale Lakes, Fla). I have a couple of
questions, and one of them is, indeed, your bypass and ischemic
times were longer in this subset of patients. Have you in fact broken
downwith time to see if there has been improvement in this overall,
because I know in my own experience that the times in the first few
cases have dramatically improved over the last several months.
DrMihaljevic. That is true. In regard to ischemic and cardiopul-
monary bypass time, I would just like to remind you that the abso-
lute crossclamp time, the length of the crossclamp time, is 80
minutes for all-comers, including those first patients who clearly
had somewhat longer bypass times, but none of our patients required
excessively long crossclamp times in excess of 120 minutes. If you
compare this with even most recently published series on complete
sternotomy or mini-anterolateral thoracotomy, you will find that
these absolute times are shorter than any of the previously published
series. And, of course, as we became more facile, the crossclamp
times have become shorter and shorter, so that our crossclampThe Journal of Thoracic and Ctime now averages approximately 70minutes regardless of the com-
plexity of MV repair that we need to do with the robot.
Dr Roberts. Two more questions. In light of your initial success
with a P2 prolapse, have you tried to do more complex repairs with
this approach? Finally, I noticed you had a significant conversion
rate when you found heavily diseased or inadequate vessels. I think
that a useful adjunct, and I wonder if you had incorporated this, is to
now use preoperative computed tomography angiography. You can
know exactly what size cannulas are going to work and which pa-
tients should not undergo operation because of atheromatous debris.
Dr Mihaljevic. To answer your first question, we use the ro-
botic approach for any patients with myxomatous MV disease re-
gardless of theMV disease complexity. And, yes, we have changed
our preoperative approach. Now we use a computer-assisted to-
mography scan and a femoral ultrasound to identify those patients
who have aortoiliac or femoral artery disease.
DrRalph Damiano (St. Louis, Mo). I disclose I am a consultant
for AtriCure and Medtronic. I was wondering why you confined
the study just to posterior leaflet disease. In your conclusion you
say that robotics is safe and effective for all myxomatous disease.
Maybe you could clarify this comment with your present experi-
ence. Are there patients with complex disease for whom you do
not recommend a robotic approach? Are your results generalizable
to more complex mitral repair?
Dr Mihaljevic.We have purposely defined this cohort as a co-
hort of patients when we did the repair to the posterior leaflet. It
doesn’t mean that these patients did not have a bileaflet prolapse
based on the preoperative echo, and quite a few patients, as you
know, who have a bileaflet prolapse can be repaired by taking
care of the posterior leaflet prolapse and putting in an annuloplasty
ring. So we wanted to have this cohort stratified in such a way that
it reflects accurately the procedural complexity. I think your com-
ment is relevant.
I have to say today in our current practice, as I mentioned be-
fore, robotic MV repair is offered to all patients with myxomatous
MV disease regardless of the complexity of their disease.
Dr Damiano. I noticed you did not present any cost data. Did
you look at whether there were increased hospital costs by using
a robotic system?
DrMihaljevic. The purpose of this study is to assess the proce-
dural safety and efficacy. We are actively looking into cost, and not
only cost of hospitalization but the costs and benefits of this pro-
cedure that extend beyond the hospital stay, and we hope to have
data to present soon, but just to share with you that there is a minor
difference in hospital cost.
Dr Damiano. In the patients who underwent mini-anterolateral
thoracotomies, what was your surgical technique? What was the
size of the thoracotomy? Did you try to avoid rib spreading? Did
you use specialized instrumentation? You can make a very small
incision with current techniques.
DrMihaljevic.Yes, it is a very small incision, anterolateral tho-
racotomy, sometimes without rib spreading, sometimes with rib
spreading, long-shafted instruments, most of the times direct trans-
thoracic crossclamping, occasional endo balloon.
Dr Antonio Laudito (Wichita, Kan). I was a bit surprised, and I
would like to know what you think. One of the minimal approaches
to attack the MV that Dr Larry Cohn proposes is the lower inferior
sternotomy, and, despite that, you presented the upper part. Theardiovascular Surgery c Volume 141, Number 1 79
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you. You use the same perfusion, cannulation, cardioplegia strategy
as inmedian sternotomy.Youdon’t needdouble lumen. It is a simple
approach if you are on top of theMV.And Iwaswondering,what do
you think about this approach that I didn’t see mentioned?
Dr Mihaljevic. Having been trained at the Brigham, I am per-
fectly familiar with it. A partial sternotomy does the same thing.
With the partial upper sternotomy, it is direct central cannulation,
usual instruments. It is just a preferred approach at the Cleveland
Clinic. But I am familiar with Dr Cohn’s approach and have done it
many times.
Dr Robert Higgins (Chicago, Ill). Impressive data. Do you
have any information about the completeness of follow-up, your
mortality after hospitalization, and the efficacy of the repair be-
yond hospitalization?
DrMihaljevic.We are going to have a complete 2-year follow-
up soon. As you may have noticed, this cohort included patients up
to January of 2009, so wewill have 2-year completeness data soon.
We have not had a single mortality beyond the usual 30 days, an in-
hospital mortality, that we know for a fact.
Dr Higgins. And the completeness of your follow-up?
Dr Mihaljevic. As I said, we have not completed a 2-year
follow-up because this is a recent study.
Dr David Adams (New York, NY). I am an inventor of annulo-
plasty rings with Edwards Lifesciences.
Tommy, I rise to congratulate you. This is a master series by
master surgeons. Your robotic series over a 2-year period is really
unbelievable, an amazing amount of work.APPENDIX 1. Variables used in the analyses
Demographics Age,*,z,{ sex,y,x,{ height (cm), weigh
Cardiac morbidity Atrial fibrillation,z,{ ventricular arrhy
Noncardiac comorbidity Chronic obstructive pulmonary diseas
smokingy,z
Laboratory medicine Blood urea nitrogen (mg/dL),x,{ chol
lipoprotein (mg/dL), creatinine (mg
Preoperative symptoms New York Heart Association function
Experience Interval (years) from January 2006 to
Preoperative echocardiogram values MV regurgitation,y,x aortic valve regu
systolic dysfunction (1 ¼ none, 2 ¼
end-diastolic volume (mL),y LV inn
shortening, LVejection fraction (%)
LV relative wall thickness (mm), LV
systolic pressure (mm Hg)k
MV pathology MV calcification,z posterior chordal r
ANT, Mini-anterolateral thoracotomy; CST, complete sternotomy; LV, left ventricular;MV,
ROB parsimonious model. yVariables in CST versus ROB saturated model. zVariables in P
kVariables in ANT versus ROB parsimonious model. {Variables in ANT versus ROB satu
80 The Journal of Thoracic and Cardiovascular SurgeI have 2 short questions. One, you didn’t show us a summary
of techniques. Have you altered your techniques of valve repair
based on robotics, for instance, less resection, less sliding plasty,
more polytetrafluoroethylene? Second, it looks like from your
data that at least in well-selected patients with degenerative
and predominantly posterior leaflet prolapse you could offer
many different incision options reproducibly. So institutionally
how are you approaching that? Obviously different surgeons
have different skill sets and biases. Are you offering approaches
to all patients or is that still surgeon based? I think it is an inter-
esting thing for you to comment on. Congratulations on your fine
series.
Dr Mihaljevic. To answer your question first, yes, just like any
other surgical technique, our repair techniques have evolved over
time. Generally speaking, for patients who have a limited MV pro-
lapse, we would use resectional techniques; for those who have
a more diffuse MV prolapse, whether it is the bileaflet or the pos-
terior leaflet, we tend toward no resection and placement of artifi-
cial chordae, and it has been a more common practice in the recent
year, also.
When it comes to offering a patient an appropriate procedure,
we offer the patient an entire spectrum of the procedure and essen-
tially tailor the procedure to the patient. We always tell a patient
that our primary goal is to do a safe and effective operation and
our secondary goal is to do it through the smallest incision possi-
ble, and if we cannot do a safe and effective operation through
a small incision, we will use an incision that will allow us to do
a safe operation.t (kg),* body surface area (m2), body mass index (kg/m),x,{
thmia, heart failure
e, hypertension, peripheral arterial disease,k renal disease, diabetes, stroke,
esterol (mg/dL),y,x low-density lipoprotein (mg/dL), high-density
/dL), hematocrit (%),y,k bilirubin (mg/dL),x triglycerides (mg/dL)
al class (I–IV),*,x,{
index operation
rgitation,y,x left atrial diameter (cm), left atrial systolic area (cm2), LV
mild, 3 ¼ moderate, 4 ¼ severe), LV inner diastolic diameter (cm), LV
er systolic diameter (cm),x LVend-systolic volume (mL), LV fractional
,y posteriorwall thickness (cm),z intraventricular septalwall thickness (cm),
mass (g),y tricuspid valve regurgitation velocity (m/s), right ventricular
upturek
mitral valve; PST, partial sternotomy; ROB, robotic surgery. *Variables in CST versus
ST versus ROB parsimonious model. xVariables in PST versus ROB saturated model.
rated model.
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